

The University of Texas MD Anderson Cancer Center Disclosure Policy for Program Chair(s), Planning Committee Members, Teachers, or Authors and CME Activity Reviewers

The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee member, faculty/teacher/author, and CME activity reviewer relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.

The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all conflicts of interest prior to this activity. For information on this process, please contact the Department of Continuing Professional Education at 713/792-5357.

DISCLOSURE INFORMATION

FACULTY/PROGRAM PLANNING COMMITTEE MEMBERS/CME ACTIVITY REVIEWERS

Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below.

<u>FACULTY</u>	<u>COMMERCIAL INTEREST</u>
Rodabe Amaria, MD	<u>Grant or Research Support:</u> Merck, Bristol-Myers Squibb, Genentech, Iovance, Novartis; <u>Advisory committees/review panels/board membership:</u> Nektar, Iovance
Kenneth A. Bauer, MD	<u>Paid Consultant:</u> Bristol-Myers Squibb, Takeda
Marcia Brose, MD, PhD	<u>Grant or Research Support:</u> Bayer/Loxo, Blueprint Meds Corp, Eisai, Exelixis; <u>Paid Consultant:</u> Bayer and Eisai; <u>Honoraria:</u> Bayer/Loxo, Eisai; <u>Advisory committees/review panels/board membership:</u> Bayer/Loxo, Eisai
Lauren Byers, MD	<u>Grant or Research Support:</u> Tolero Pharmaceuticals; <u>Paid Consultant:</u> AstraZeneca, GenMab, Sierra Oncology, Pharma Mar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, Pfizer, Jazz Pharmaceuticals; <u>Advisory committees/review panels/board membership:</u> AstraZeneca, GenMab, Sierra Oncology, Pharma Mar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, Pfizer, Jazz Pharmaceuticals
Lisa Carey, MD	<u>Grant or Research Support:</u> Innocrin Pharma, Syndax, Immunomedics, Novartis, Nanostring, Abbvie, Seattle Genetics; <u>Other relevant financial or material interests:</u> Spouse: Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme.
Mariana Chavez Mac Gregor, MD	<u>Grant or Research Support:</u> Novartis (institution); <u>Advisory committees/review panels/board membership:</u> AstraZeneca, Roche, Pfizer, Abbott, Novartis
Jorge Cortes, MD	<u>Grant or Research Support:</u> Novartis, Pfizer, Takeda, Sun Pharma (all to my former and/or current institution); <u>Paid Consultant:</u> Novartis, Pfizer, Takeda
Daniel J. DeAngelo, MD, PhD	<u>Grant or Research Support:</u> AbbVie, Novartis, Blueprint, Glycomimetics; <u>Paid Consultant:</u> Amgen, Agios, Autolus, Forty-Seven, Incyte, Jazz Pharma, Pfizer, Servier, Takeda
Courtney DiNardo, MD	<u>Grant or Research Support:</u> Agios, AbbVie, Celgene, Daiichi-Sankyo; <u>Honoraria:</u> Immune Onc Therapeutics, Novartis; <u>Advisory committees/review panels/board membership:</u> Agios, AbbVie, Celgene, Notable Labs; <u>Stocks or stock options:</u> Notable Labs
Nathan Fowler, MD	<u>Grant or Research Support:</u> Roche, Celgene, Gilead, TG Therapeutics; <u>Advisory committees/ review panels/board membership:</u> Roche, Celgene, Gilead, TG Therapeutics

2020 Comprehensive Board Review in Hematology and Medical Oncology

FACULTY	COMMERCIAL INTEREST (CONTINUED)
Michael Frumovitz, MD, MPH	<u>Grant or Research Support</u> : AstraZeneca, Tesaro/GSK; <u>Paid Consultant</u> : Stryker; <u>Speaker's Bureau</u> : Stryker
Nasser Hanna, MD	<u>Grant or Research Support</u> : Merck, Bristol-Myers Squibb, AstraZeneca, Genentech; <u>Advisory committees/review panels/board membership</u> : Beyond Spring
Matthew Heeney, MD	<u>Grant or Research Support</u> : Cylcerion, Pfizer, Novartis, Micelle Biopharma; <u>Paid Consultant</u> : FORMA Therapeutics, Novartis, Micelle Biopharma, AstraZeneca, Dova Pharmaceuticals, Global Blood Therapeutics Inc.
Claudine Isaacs, MD	<u>Grant or Research Support</u> : Tesaro (Institution); <u>Paid Consultant</u> : AstraZeneca, Pfizer, Novartis, PUMA, Genentech, Seattle Genetics; <u>Speaker's Bureau</u> : Genentech
Eric Jonasch, MD	<u>Grant or Research Support</u> : Exelixis, Merck, Pfizer; <u>Paid Consultant</u> : Eisai, Exelixis, Merck, Pfizer
Tapan Kadia, MD	<u>Grant or Research Support</u> : Bristol-Myers Squibb, Pfizer, Genentech, Jazz Pharma, AstraZeneca, Celgene, Amgen, Ascentage, Cellenkos, AbbVie; <u>Paid Consultant</u> : Novartis, Pfizer, Genentech, AbbVie, Jazz Pharma
Scott Kopetz, MD, PhD	<u>Grant or Research Support</u> : Amgen, Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Eli Lilly; <u>Advisory committees/review panels/board membership</u> : Roche, Genentech, EMD Serono, Merck, Karyopharm Therapeutics, Amal Therapeutics, Navire Pharma, Symphogen, Holy Stone, Biocartis, Amgen, Novartis, Eli Lilly; Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Bayer Health, Pierre Fabre, EMD Serono, Redx Pharma; <u>Ownership Interest (stocks, stock option)</u> : MolecularMatch, Navire Pharma
Mark Lewis, MD	<u>Advisory committees/review panels/board membership</u> : Natera (advisory board)
Jennifer K. Litton, MD	<u>Grant or Research Support</u> : Genentech, EMD-Serono, Pfizer, AstraZeneca, Zenith; <u>Advisory committees/review panels/board membership</u> : Pfizer, Ayala Pharmaceuticals
Alice Ma, MD	<u>Grant or Research Support</u> : Takeda; <u>Paid Consultant</u> : Accordant; <u>Advisory committees/review panels/board membership</u> : Takeda, Novo Nordisk
Martha P. Mims, MD, PhD	<u>Grant or Research Support</u> : Clinical Trial Support: Celgene, Aveo, Pfizer
Stephan Moll, MD	<u>Honoraria</u> : Diagnostica Stago
Loretta Nastoupil, MD	<u>Grant or Research Support</u> : Bristol-Myers Squibb/Celgene, Genentech, Janssen, Novartis; <u>Honoraria</u> : Bayer, Celgene, Genentech, Janssen, Kite/Gilead, Novartis
Susan O'Brien, MD	<u>Grant or Research Support</u> : Kite, Regeneron, Acerta, Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis; <u>Paid Consultant</u> : Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc, AbbVie, Alexion, Verastem, Eisai, Juno Therapeutics; Vida Ventures, Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis
Timothy S. Olson, MD, PhD	<u>Paid Consultant</u> : Bluebird Bio
Antonio Omuro, MD	<u>Paid Consultant</u> : Merck
Shreyaskumar Patel, MD	<u>Grant or Research Support</u> : Blueprint Medicines, Hutchison Med Pharma; <u>Paid Consultant</u> : DSI, Dova, Deciphera, Epizyme, Bayer
Barbara Pro, MD	<u>Grant or Research Support</u> : Seattle Genetics, Takeda, Verastem, Celgene; <u>Paid Consultant</u> : Seattle Genetics, Takeda; <u>Honoraria</u> : Seattle Genetics, Takeda
Alvin Schmaier, MD	<u>Grant or Research Support</u> : Shire/Takeda; <u>Paid Consultant</u> : Intellia, CSL Behring

2020 Comprehensive Board Review in Hematology and Medical Oncology

FACULTY	COMMERCIAL INTEREST (CONTINUED)
Nicholas Short, MD	<u>Grant or Research Support</u> : Takeda Oncology; <u>Paid Consultant</u> : Takeda Oncology, AstraZeneca; <u>Honoraria</u> : Amgen
Arlene Siefker-Radtke, MD	<u>Grant or Research Support</u> : Basilea Pharmaceutical, Bristol-Myers Squibb, Janssen, Merck, Millennium, Mirati, Nektar Therapeutics; <u>Paid Consultant</u> : AstraZeneca, Bavarian Nordic, Genentech, Janssen, Merck, Mirati, Nektar Therapeutics, Seattle Genetics; <u>Speaker's Bureau</u> : Janssen; <u>Advisory committees/review panels/board membership</u> : AstraZeneca, Bavarian Nordic, Genentech, Janssen, Merck, Mirati, Nektar Therapeutics, Seattle Genetics
Ibena Romina Sosa, MD, PhD	<u>Employment</u> : Bristol-Myers Squibb – spouse (My spouse's employment at BMS as a translational pathologist will have no influence on the content of the discussion).
Srdan Verstovsek, MD, PhD	<u>Grant or Research Support</u> : Incyte Corp, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma Corp, Genentech, Blueprint Medicines Corp, Novartis, Sierra Oncology, Pharma Essentia, AstraZeneca, Ital Pharma, Protagonist Therapeutics, Constellation Pharmaceuticals, Kartos Therapeutics, Prelude Therapeutics
Shannon Westin, MD, MPH	<u>Grant or Research Support</u> : AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Bayer, Cotinga Pharmaceuticals, ArQule; <u>Paid Consultant</u> : AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Merck, Pfizer, Zentalis, Eisai, Circulogene
William N. William, Jr., MD	<u>Grant or Research Support</u> : AstraZeneca, Merck, Bristol-Myers Squibb; <u>Honoraria</u> : AstraZeneca, Merck, Bristol-Myers Squibb, Roche, Bayer, Pfizer, Boehringer Ingelheim
Harry Yoon, MD	<u>Grant or Research Support</u> : Eli Lilly, Genetech/Roche, Boston, Merck, LSK; <u>Advisory committees/review panels/board membership</u> : LSK, Merck, MacroGenics, BeiGene, ALX Oncology, BMS – advisory board

PLANNING COMMITTEE MEMBERS	COMMERCIAL INTEREST
Alessandra Ferrajoli, MD	<u>Grant or Research Support</u> : Celgene Inc, Acerta Pharma, BeiGene
Bonnie Glisson, MD	<u>Grant or Research Support</u> : To my institution: Pfizer, Cue-Bio ISA Pharmaceuticals
Tapan Kadia, MD	<u>Grant or Research Support</u> : AbbVie, Amgen, Bristol-Myers Squibb, BioLine Rx, Celgene, Jazz Pharma, Pfizer; <u>Advisory committees/review panels/board membership</u> : AbbVie, Amgen, Genentech, Jazz Pharma, Novartis, Pfizer, Takeda
Martha P. Mims, MD, PhD	<u>Grant or Research Support</u> : Clinical Trial Support: Celgene, Aveo, Pfizer, Incyte, DeNova; <u>Ownership Interest (stock, stock options)</u> : Amgen, Biogen
Shreyaskumar Patel, MD	<u>Grant or Research Support</u> : Blueprint Medicines, Janssen, Eisai; <u>Paid Consultant</u> : Novartis, Dova, Daiichi, Deciphera, Epizyme

2020 Comprehensive Board Review in Hematology and Medical Oncology

Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have indicated no financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity.

FACULTY

Lynne Abruzzo, MD, PhD Merav Bar, MD Nancy Berliner, MD Tina Cascone, MD, PhD Alice Chen, MD, PhD	Ravin Garg, MD Timothy D. Gilligan, MD Whitney Lewis, PharmD Ang Li, MD, MS Nicholas Mitsiades, MD, PhD	Brian Primeaux, PharmD S. Vincent Rajkumar, MD A. Koneti Rao, MD Samuel Shelburne, MD, PhD Robert Wolff, MD Chrystia Zobniw, PharmD
---	---	--

PLANNING COMMITTEE MEMBERS

Nishin Bhadkamkar, MD	Felisha Estelle	Sharon Giordano, MD
-----------------------	-----------------	---------------------

CME ACTIVITY REVIEWERS/APPROVERS

Diane Bodurka, MD (Approver)	Josiah Halm, MD	Brian R. Weston, MD
Karin Woodman, MD		

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented.